Evidence map›Paper›PMID 29316212›Full record

ArticleJournal of clinical hypertension (Greenwich, Conn.)2018

Renal artery stenting for atherosclerotic renal artery stenosis identified in patients with coronary artery disease: Does captopril renal scintigraphy predict outcomes?

Spyros Stratigis, Kostas Stylianou, Periklis P Kyriazis, Eleftheria-Kleio Dermitzaki, Dimitra Lygerou, Paraskevi Syngelaki, Stavros Stratakis, Sophia Koukouraki, Fragiskos Parthenakis, Dimitrios Tsetis and 1 more

Abstract read
In one paragraph

Article in Journal of clinical hypertension (Greenwich, Conn.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Renal artery stenosis in China: The state of changes.Journal of clinical hypertension (Greenwich, Conn.) · 2018
    Article
  5. Article
  6. Possible interesting link between Janus kinase 2 mutation and renovascular hypertension.Journal of clinical hypertension (Greenwich, Conn.) · 2018
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Spyros StratigisDepartment of Nephrology, Heraklion University Hospital, Crete, Greece.
Kostas StylianouDepartment of Nephrology, Heraklion University Hospital, Crete, Greece.ORCID 0000-0003-3678-9421
Periklis P KyriazisDepartment of Medicine, Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA, USA.
Eleftheria-Kleio DermitzakiDepartment of Nephrology, Heraklion University Hospital, Crete, Greece.
Dimitra LygerouDepartment of Nephrology, Heraklion University Hospital, Crete, Greece.
Paraskevi SyngelakiDepartment of Nephrology, Heraklion University Hospital, Crete, Greece.
Stavros StratakisDepartment of Nephrology, Heraklion University Hospital, Crete, Greece.
Sophia KoukourakiDepartment of Nuclear Medicine, Heraklion University Hospital, University of Crete, Crete, Greece.
Fragiskos ParthenakisDepartment of Cardiology, Heraklion University Hospital, University of Crete, Crete, Greece.
Dimitrios TsetisInterventional Radiology Unit, Department of Radiology, Heraklion University Hospital, University of Crete, Crete, Greece.
Eugene DaphnisDepartment of Nephrology, Heraklion University Hospital, Crete, Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The authors evaluated the effectiveness of percutaneous renal revascularization (PRR) with stenting for the treatment of atherosclerotic renal artery stenosis (ARAS) in patients with coronary artery disease and the usefulness of captopril renal scintigraphy for predicting clinical outcomes after PRR. Sixty-four consecutive patients, referred for evaluation of suspected ARAS, after coronary angiography, underwent baseline captopril renal scintigraphy followed by renal angiography. Forty-four patients (68.7%) were diagnosed with a significant ARAS≥ 60% and were treated with PRR plus medical therapy. Twenty-four months after PRR, 86.4% and 73.3% of patients showed a hypertension and renal benefit, respectively. Captopril renal scintigraphy positivity had moderate sensitivity and high specificity in predicting a hypertension and renal benefit. In patients with ARAS≥ 70%, the sensitivity and specificity were 100% for both a hypertension and renal benefit.PRR for ARAS conferred a substantial benefit in patients with a high coronary artery disease burden. Captopril renal scintigraphy was highly accurate in predicting clinical outcomes.

Indexed as

AngioplastyHypertension, RenovascularRenal ArteryRenal Artery ObstructionStentsAgedAngiographyAngiotensin-Converting Enzyme InhibitorsCaptoprilCoronary Artery DiseaseFemaleHumansKidneyMaleMiddle AgedPredictive Value of TestsAngiotensin-Converting Enzyme InhibitorsCaptoprilcaptopril renal scintigraphypercutaneous renal revascularizationrenal artery stenosisrenovascular hypertension

Identifiers

PMID29316212
PMCPMC8030775

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.